HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MDAI
Spectral AI, Inc.
MDAI lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MDAI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
MDAI's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MDAI PE Valuation
MDAI has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MDAI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect MDAI's losses to grow, with revenue declining.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MDAI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.33 | +$0.37 |
| Q1 2026 | -$0.51 | +$0.04 |
| Q4 2025 | -$0.29 | +$0.56 |
| Q3 2025 | -$0.75 | +$0.05 |
| Q2 2025 | -$0.70 | +$0.79 |
MDAI has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MDAI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over MDAI on profitability, with a higher operating margin.
MDAI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.5M | -30% |
| Q1 2026 | $4M | -40% |
| Q4 2025 | $4.1M | -46% |
| Q3 2025 | $3.8M | -54% |
| Q2 2025 | $5.1M | -32% |
| Q1 2025 | $6.7M | +6% |
| Q4 2024 | $7.6M | +44% |
| Q3 2024 | $8.2M | +138% |
MDAI's revenue has slid since its 2024 peak: $4M last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -123% | -81 points |
| Q1 2026 | -49% | -36 points |
| Q4 2025 | -55% | -40 points |
| Q3 2025 | -88% | -77 points |
| Q2 2025 | -42% | -9.3 points |
| Q1 2025 | -13% | +21 points |
| Q4 2024 | -15% | +41 points |
| Q3 2024 | -11% | +110 points |
MDAI's operating margin was −123% last quarter, down 81 points from the same quarter a year ago, near the bottom of its range since 2023.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MDAI on cash generation, producing positive trailing cash flow while its opponent burns cash.
MDAI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.1M | -$735K |
| Q1 2026 | -$3.7M | -$2.2M |
| Q4 2025 | -$2.6M | -644% |
| Q3 2025 | -$2.5M | -$875K |
| Q2 2025 | -$3.4M | +$2M |
| Q1 2025 | -$1.5M | +$1.2M |
| Q4 2024 | $469K | +$2.8M |
| Q3 2024 | -$1.6M | +$8.9M |
MDAI has burned cash in almost every quarter: −$13M over the past year, against −$6M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MDAI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MDAI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +324K shares |
| 1 year | +26% | +6.7M shares |
MDAI has 32M diluted shares, up 26% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MDAI Net Leverage
MDAI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MDAI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 23.5 | Neutral |
MDAI's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MDAI PE vs Healthcare Sector
MDAI has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MDAI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.53 | 12% below |
| 20 week MA | $1.60 | 16% below |
| 50 week MA | $1.67 | 19% below |
| 100 week MA | $1.81 | 25% below |
| 200 week MA | $3.38 | 60% below |
MDAI is in a downtrend: it's below all five of its weekly moving averages, and 60% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MDAI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.72 | $9.82 | +1% |
| 2022 | $9.82 | $10.2 | +3.9% |
| 2023 | $10.2 | $2.46 | -76% |
| 2024 | $2.46 | $2.75 | +12% |
| 2025 | $2.75 | $1.42 | -48% |
| 2026 YTD | $1.42 | $1.35 | -4.9% |
MDAI has the edge over HIMS on returns for 2026, with the stronger performance.